Sanofi and VNVC Open New Vaccine Manufacturing Plant in Vietnam

Sanofi (NASDAQ:SNY), in partnership with Vietnam Vaccine JSC (VNVC), officially launched a state-of-the-art vaccine production facility in Vietnam, marking a major step in boosting the country’s pharmaceutical manufacturing capabilities. The new plant is designed to supply vaccines for both domestic distribution and global export, supporting broader public health goals across Asia and beyond.

The inauguration ceremony, held on Tuesday, was attended by French President Emmanuel Macron during his diplomatic visit to the Southeast Asian nation, underscoring the importance of international collaboration in advancing healthcare access.

Strategically located to serve Vietnam’s growing healthcare needs, the facility enhances local vaccine self-sufficiency while contributing to the global vaccine supply chain. It is part of Sanofi’s ongoing effort to expand its footprint in emerging markets and reinforce its role as a global vaccine leader.

The launch comes amid heightened global attention on vaccine access and preparedness following recent pandemics. By leveraging cutting-edge technology and Sanofi’s extensive vaccine expertise, the facility aims to strengthen Vietnam’s position as a regional hub for pharmaceutical innovation and production.

This initiative reflects Sanofi’s commitment to investing in sustainable healthcare infrastructure and VNVC’s mission to improve immunization access across Vietnam. The collaboration also aligns with government goals to attract high-quality foreign investment in biotechnology and life sciences.

With the new facility operational, Sanofi and VNVC are well-positioned to meet growing demand for essential vaccines, not only within Vietnam but across neighboring countries, contributing to improved regional health outcomes.

The opening of this manufacturing site marks a significant milestone in Vietnam’s healthcare development, offering long-term benefits in vaccine accessibility, economic growth, and international cooperation in the pharmaceutical sector.